Skip to main content

Table 1 COVID-19 studies reported in ImmPort as of April 18, 2021

From: CIDO ontology updates and secondary analysis of host responses to COVID-19 infection based on ImmPort reports and literature

ImmPort Study ID Title PMID Comments Citation
SDY1667 Cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans 32753554 Shared epitopes with common cold coronaviruses [20]
SDY1640 T and B cell responses to SARS-CoV-2 coronavirus 32473127 Cytokine signatures/markers [26]
SDY1662 An inflammatory cytokine signature predicts Covid-19 severity and survival 32839624 Inflammatory cytokine signatures [30]
SDY1665 Longitudinal analyses reveal immunological misfiring in severe COVID-19 (Companion study to SDY1648) 32717743 Cytokine signatures [31]
SDY1648 Sex differences in immune responses to SARS-CoV-2 (Companion study to SDY1655) 32846427 Overlapped genes with significant differences in female and male patients [12]
SDY1641 Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension 32228222 RAS inhibitor drugs effective against hypertension [49]